Genetic analysis of type 1 diabetes: Embryonic stem cells as new tools to unlock biological mechanisms in type 1 diabetes

Review of Diabetic Studies

Volumn 9, Issue 4, 2012, Pages 137-147

  Holmes, Nick ^a   Cooke, Anne ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Embryonic stem cell; Gene; Haplotype; NOD; Nonobese diabetic mouse; Susceptibility; Type 1 diabetes

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 21;

ALLERGIC ENCEPHALOMYELITIS; CHIMERA; CHROMOSOME 3; EMBRYONIC STEM CELL; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; GENETIC MANIPULATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MORPHOLOGICAL TRAIT; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE;

EID: 84879130419     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2012.9.137     Document Type: Review

References (60)

1. Leiter EH. Nonobese diabetic mice and the genetics of diabetes susceptibility. Curr Diab Rep 2005. 5:141-148.
2. Burren OS, Adlem EC, Achuthan P, Christensen M, Coulson RM, Todd JA. T1DBase: update 2011, organization and presentation of large-scale data sets for type 1 diabetes research. Nucleic Acids Res 2011. 39:D997-D1001.
3. Cervino AC, Gosink M, Fallahi M, Pascal B, Mader C, Tsinoremas NF. A comprehensive mouse IBD database for the efficient localization of quantitative trait loci. Mamm Genome 2006. 17:565-574.
4. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007. 39:329-337.
5. Eizirik DL, Sammeth M, Bouckenooghe T, Bottu G, Sisino G, Igoillo-Esteve M, Ortis F, Santin I, Colli ML, Barthson J, et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet 2012. 8:e1002552.
6. Acha-Orbea H, McDevitt HO. The first external domain of the nonobese diabetic mouse class II I-Abeta chain is unique. Proc Natl Acad Sci USA 1987. 84:2435-2439.
7. Liu GY, Baker D, Fairchild S, Figueroa F, Quartey-Papafio R, Tone M, Healey D, Cooke A, Turk JL, Wraith DC. Complete characterization of the expressed immune response genes in Biozzi AB/H mice: structural and functional identity between AB/H and NOD A region molecules. Immunogenetics 1993. 37:296-300.
8. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, McDermott M, Sinha AA, Timmerman L, Steinman L, et al. A molecular basis for MHC class II-associated autoimmunity. Science 1988. 240:1003-1009.
9. Lund T, O'Reilly L, Hutchings P, Kanagawa O, Simpson E, Gravely R, Chandler P, Dyson J, Picard JK, Edwards A, et al. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alphachain. Nature 1990. 345:727-729.
10. O'Reilly LA, Healey D, Simpson E, Chandler P, Lund T, Ritter MA, Cooke A. Studies on the thymus of non-obese diabetic (NOD) mice: effect of transgene expression. Immunology 1994. 82:275-286.
11. Todd JA, Aitman TJ, Cornall RJ, Ghosh S, Hall JR, Hearne CM, Knight AM, Love JM, McAleer MA, Prins JB, et al. Genetic analysis of autoimmune type 1 diabetes mellitus in mice. Nature 1991. 351:542-547.
12. Prins JB, Todd JA, Rodrigues NR, Ghosh S, Hogarth PM, Wicker LS, Gaffney E, Podolin PL, Fischer PA, Sirotina A, Peterson LB. Linkage on chromosome 3 of autoimmune diabetes and defective Fc receptor for IgG in NOD mice. Science 1993. 260:695-698.
13. Podolin PL, Denny P, Lord CJ, Hill NJ, Todd JA, Peterson LB, Wicker LS, Lyons PA. Congenic mapping of the insulin-dependent diabetes (Idd) gene, Idd10, localizes two genes mediating the Idd10 effect and eliminates the candidate Fcgr1. J Immunol 1997. 159:1835-1843.
14. Lyons PA, Armitage N, Argentina F, Denny P, Hill NJ, Lord CJ, Wilusz MB, Peterson LB, Wicker LS, Todd JA. Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res 2000. 10:446-453.
15. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci USA 2008. 105:14028-14033.
16. Sutherland AP, Van Belle T, Wurster AL, Suto A, Michaud M, Zhang D, Grusby MJ, von Herrath M. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009. 58:1144-1155.
17. McGuire HM, Walters S, Vogelzang A, Lee CM, Webster KE, Sprent J, Christ D, Grey S, King C. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2011. 60:867-875.
18. Van Belle TL, Nierkens S, Arens R, von Herrath MG. Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 2012. 36:1060-1072.
19. Schorle H, Holtschke T, Hünig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991. 352:621-624.
20. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene-targeting in mouse embryo-derived stem cells. Cell 1987. 51:505-512.
21. Malissen M, Gillet A, Ardouin L, Bouvier G, Trucy J, Ferrier P, Vivier E, Malissen B. Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. EMBO J 1995. 14:4641-4653.
22. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 2005. 102:11823-11828.
23. Kanagawa O, Xu G, Tevaarwerk A, Vaupel BA. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-g receptor loci. J Immunol 2000. 164:3919-3923.
24. Schalkwyk LC, Fernandes C, Nash MW, Kurrikoff K, Vasar E, Koks S. Interpretation of knockout experiments: the congenic footprint. Genes Brain Behav 2007. 6:299-303.
25. Valor LM, Grant SG. Clustered gene expression changes flank targeted gene loci in knockout mice. PLoS One 2007. 2:e1303.
26. McAleer MA, Reifsnyder P, Palmer SM, Prochazka M, Love JM, Copeman JB, Powell EE, Rodrigues NR, Prins JB, Serreze DV, et al. Crosses of NOD mice with the related NON strain. A polygenic model for IDDM. Diabetes 1995. 44:1186-1195.
27. Gonzalez A, Katz JD, Mattei MG, Kikutani H, Benoist C, Mathis D. Genetic control of diabetes progression. Immunity 1997. 7:873-883.
28. Hamilton-Williams EH, Serreze DV, Charlton B, Johnson EA, Marron MP, Mullbacher A, Slattery RM. Transgenic rescue implicates beta2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice. Proc Natl Acad Sci USA 2001. 98:11533-11538.
29. Kissler S, Stern P, Takahashi K, Hunter K, Peterson LB, Wicker LS. In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes. Nat Genet 2006. 38:479-483.
30. Gerold KD, Zheng P, Rainbow DB, Zernecke A, Wicker LS, Kissler S. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 2011. 60:1955-1963.
31. Zheng P, Kissler S. PTPN22 Silencing in the NOD Model Indicates the Type 1 Diabetes-Associated Allele Is Not a Loss-of-Function Variant. Diabetes 2012. In press.
32. Nagafuchi S, Katsuta H, Kogawa K, Akashi T, Kondo S, Sakai Y, Tsukiyama T, Kitamura D, Niho Y, Watanabe T. Establishment of an embryonic stem (ES) cell line derived from a non-obese diabetic (NOD) mouse: in vivo differentiation into lymphocytes and potential for germ line transmission. FEBS Lett 1999. 455:101-104.
33. Arai S, Minjares C, Nagafuchi S, Miyazaki T. Improved experimental procedures for achieving efficient germ line transmission of nonobese diabetic (NOD)-derived embryonic stem cells. Exp Diabesity Res 2004. 5:219-226.
34. Chen J, Reifsnyder PC, Scheuplein F, Schott WH, Mileikovsky M, Soodeen-Karamath S, Nagy A, Dosch MH, Ellis J, Koch-Nolte F, Leiter EH. "Agouti NOD": identification of a CBA-derived Idd locus on Chromosome 7 and its use for chimera production with NOD embryonic stem cells. Mamm Genome 2005. 16:775-783.
35. Brook FA, Evans EP, Lord CJ, Lyons PA, Rainbow DB, Howlett SK, Wicker LS, Todd JA, Gardner RL. The derivation of highly germline-competent embryonic stem cells containing NOD-derived genome. Diabetes 2003. 52:205-208.
36. Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P, Smith A. The ground state of embryonic stem cell self-renewal. Nature 2008. 453:519-523.
37. Ohta H, Ohinata Y, Ikawa M, Morioka Y, Sakaide Y, Saitou M, Kanagawa O, Wakayama T. Male germline and embryonic stem cell lines from NOD mice: efficient derivation of GS cells from a nonpermissive strain for ES cell derivation. Biol Reprod 2009. 81:1147-1153.
38. Yang W, Wei W, Shi C, Zhu J, Ying W, Shen Y, Ye X, Fang L, Duo S, Che J, et al. Pluripotin combined with leukemia inhibitory factor greatly promotes the derivation of embryonic stem cell lines from refractory strains. Stem Cells 2009. 27:383-389.
39. Hanna J, Markoulaki S, Mitalipova M, Cheng AW, Cassady JP, Staerk J, Carey BW, Lengner CJ, Foreman R, Love J, et al. Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell 2009. 4:513-524.
40. Nichols J, Jones K, Phillips JM, Newland SA, Roode M, Mansfield W, Smith A, Cooke A. Validated germline-competent embryonic stem cell lines from nonobese diabetic mice. Nat Med 2009. 15:814-818.
41. Morgan MA, Muller PS, Mould A, Newland SA, Nichols J, Robertson EJ, Cooke A, Bikoff EK. The Nonconventional MHC class II molecule DM governs diabetes susceptibility in NOD mice. PLoS One 2013. 8:e56738.
42. Kamanaka M, Rainbow D, Schuster-Gossler K, Eynon EE, Chervonsky AV, Wicker LS, Flavell RA. Amino acid polymorphisms altering the glycosylation of IL-2 do not protect from type 1 diabetes in the NOD mouse. Proc Natl Acad Sci USA 2009. 106:11236-11240.
43. Liew CG, Andrews PW. Stem cell therapy to treat diabetes mellitus. Rev Diabet Stud 2008. 5(4):203-219.
44. Wallis RH, Wang K, Marandi L, Hsieh E, Ning T, Chao GY, Sarmiento J, Paterson AD, Poussier P. Type 1 diabetes in the BB rat: a polygenic disease. Diabetes 2009. 58:1007-1017.
45. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, Jenkins SS, Wood A, Cui X, Meng X, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 2009. 325:433.
46. Mashimo T, Takizawa A, Voigt B, Yoshimi K, Hiai H, Kuramoto T, Serikawa T. Generation of knockout rats with X-linked severe combined immunodeficiency (XSCID) using zinc-finger nucleases. PLoS One 2010. 5:e8870.
47. Cui X, Ji D, Fisher DA, Wu Y, Briner DM, Weinstein EJ. Targeted integration in rat and mouse embryos with zinc-finger nucleases. Nat Biotechnol 2011. 29:64-67.
48. Tesson L, Usal C, Ménoret S, Leung E, Niles BJ, Remy S, Santiago Y, Vincent AI, Meng X, Zhang L, et al. Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 2011. 29:695-696.
49. Meyer M, Ortiz O, Hrabe de Angelis M, Wurst W, Kühn R. Modeling disease mutations by gene targeting in one-cell mouse embryos. Proc Natl Acad Sci USA 2012. 109:9354-9359.
50. Wang J, Friedman G, Doyon Y, Wang NS, Li CJ, Miller JC, Hua KL, Yan JJ, Babiarz JE, Gregory PD, Holmes MC. Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res 2012. 22:1316-1326.
51. Cohen AJ, McGill PD, Rossetti RG, Guberski DL, Like AA. Glomerulopathy in spontaneously diabetic rat. Impact of glycemic control. Diabetes 1987. 36:944-951.
52. Many MC, Maniratunga S, Denef JF. The non-obese diabetic (NOD) mouse: an animal model for autoimmune thyroiditis. Exp Clin Endocrinol Diabetes 1996. 104(Suppl 3):17-20.
53. Allen EM, Appel MC, Braverman LE. The effect of iodide ingestion on the development of spontaneous lymphocytic thyroiditis in the diabetes-prone BB/W rat. Endocrinology 1986. 118:1977-1981.
54. Thompson C, Jacobsen H, Pomeranz Krummel D, Nagai K, Cooke A. Non-depleting anti-CD4 antibody not only prevents onset but resolves sialadenitis in NOD mice. Autoimmunity 2004. 37:549-554.
55. Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med (Berl) 1997. 75:77-88.
56. Smith RJ, Sly LM. Type II collagen-induced arthritis in the diabetic-resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process. J Pharmacol Exp Ther 1996. 277:1801-1813.
57. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. Arthritis Rheum 2002. 46:1390-1398.
58. Baker D, Rosenwasser OA, O'Neill JK, Turk JL. Genetic analysis of experimental allergic encephalomyelitis in mice. J Immunol 1995. 155:4046-4051.
59. del Rio R, Noubade R, Subramanian M, Saligrama M, Diehl S, Rincon M, Teuscher C. SNPs upstream of the minimal promoter control IL-2 expression and are candidates for the autoimmune disease-susceptibility locus Aod2/Idd3/Eae3. Genes and Immunity 2008. 9:115-121.
60. Testa G, Zhang Y, Vintersten K, Benes V, Pijnappel WW, Chambers I, Smith AJ, Smith AG, Stewart AF. Engineering the mouse genome with bacterial artificial chromosomes to create multipurpose alleles. Nat Biotechnol 2003. 21:443-447.